Is Kenvue Stock Underperforming the Dow?

Company Overview - Kenvue Inc. is a consumer health company based in Summit, New Jersey, with a market capitalization of $35.4 billion, offering a wide range of over-the-counter medicines, skincare products, oral care items, and self-care solutions [1] - The company’s portfolio includes well-known brands such as Tylenol, Listerine, Neutrogena, Aveeno, and Band-Aid, establishing a strong presence in everyday healthcare and wellness [1][2] Market Position - Kenvue is classified as a large-cap stock, reflecting its size, influence, and dominance in the household and personal products industry [2] - The company benefits from a portfolio of iconic consumer health brands that enjoy strong brand loyalty and global recognition, addressing everyday health and wellness needs [2] Stock Performance - Kenvue's stock has decreased by 26.6% from its 52-week high of $25.17, reached on May 8, and has declined 14.2% over the past three months, underperforming the Dow Jones Industrial Average's 6.1% return during the same period [3] - Over the past 52 weeks, Kenvue shares have fallen 19.9%, significantly lagging behind the Dow Jones Industrial Average's 11.7% increase [4] - Year-to-date, Kenvue shares are down 13.5%, compared to the Dow Jones Industrial Average's 6.9% rise [4] Recent Earnings - Kenvue's shares surged 1.5% on August 7 following a mixed Q2 earnings release, where overall revenue declined 4% year-over-year to $3.8 billion, slightly missing consensus estimates [5] - The adjusted EPS fell 9.4% from the previous year to $0.29, but exceeded analyst expectations by a penny, which boosted investor confidence [5]